Physical and hormonal evaluation of transsexual patients during hormonal therapy

Walter Meyer, Jordan W. Finkelstein, Charles A. Stuart, Alice Webb, Edward R. Smith, Andrew F. Payer, Paul A. Walker

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The optimal hormonal therapy for transsexual patients is not known. The physical and hormonal characteristics of 38 noncastrate male-to-female transsexuals and 14 noncastrate female-to-male transsexuals have been measured before and/or during therapy with various forms and dosages of hormonal therapy. All patients were hormonally and physically normal prior to therapy. Ethinyl estradiol was superior to conjugated estrogen in suppression of testosterone and gonadotropins but equal in effecting breast growth. The changes in physical and hormonal characteristics were the same for 0.1 mg/d and 0.5 mg/d of ethinyl estradiol. The female-to-male transsexuals were well managed with a dose of intramuscular testosterone cypionate of 400 mg/month, usually given 200 mg every two weeks. The maximal clitoral length reached was usually 4 cm. Higher doses of testosterone did not further increase clitoral length or suppression of gonadotropins; lower doses did not suppress the gonadotropins. Based on the information found in this study, we recommend 0.1 mg/d of ethinyl estradiol for the noncastrate male-to-female transsexual and 200 mg of intramuscular testosterone cypionate every two weeks for the noncastrate female-to-male transsexual.

Original languageEnglish (US)
Pages (from-to)347-356
Number of pages10
JournalArchives of Sexual Behavior
Volume10
Issue number4
DOIs
StatePublished - Aug 1981

Fingerprint

Ethinyl Estradiol
Gonadotropins
Testosterone
Therapeutics
Conjugated (USP) Estrogens
Dosage Forms
Breast
Physical
Evaluation
Therapy
Transsexual
Growth
Dose
testosterone 17 beta-cypionate
Suppression
Length

Keywords

  • breast
  • clitoris
  • estrogen
  • hormone
  • testosterone
  • transsexual

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychology(all)

Cite this

Meyer, W., Finkelstein, J. W., Stuart, C. A., Webb, A., Smith, E. R., Payer, A. F., & Walker, P. A. (1981). Physical and hormonal evaluation of transsexual patients during hormonal therapy. Archives of Sexual Behavior, 10(4), 347-356. https://doi.org/10.1007/BF01565538

Physical and hormonal evaluation of transsexual patients during hormonal therapy. / Meyer, Walter; Finkelstein, Jordan W.; Stuart, Charles A.; Webb, Alice; Smith, Edward R.; Payer, Andrew F.; Walker, Paul A.

In: Archives of Sexual Behavior, Vol. 10, No. 4, 08.1981, p. 347-356.

Research output: Contribution to journalArticle

Meyer, W, Finkelstein, JW, Stuart, CA, Webb, A, Smith, ER, Payer, AF & Walker, PA 1981, 'Physical and hormonal evaluation of transsexual patients during hormonal therapy', Archives of Sexual Behavior, vol. 10, no. 4, pp. 347-356. https://doi.org/10.1007/BF01565538
Meyer W, Finkelstein JW, Stuart CA, Webb A, Smith ER, Payer AF et al. Physical and hormonal evaluation of transsexual patients during hormonal therapy. Archives of Sexual Behavior. 1981 Aug;10(4):347-356. https://doi.org/10.1007/BF01565538
Meyer, Walter ; Finkelstein, Jordan W. ; Stuart, Charles A. ; Webb, Alice ; Smith, Edward R. ; Payer, Andrew F. ; Walker, Paul A. / Physical and hormonal evaluation of transsexual patients during hormonal therapy. In: Archives of Sexual Behavior. 1981 ; Vol. 10, No. 4. pp. 347-356.
@article{ebe4d6ae9b0e4dc48e10f8c1c7716f40,
title = "Physical and hormonal evaluation of transsexual patients during hormonal therapy",
abstract = "The optimal hormonal therapy for transsexual patients is not known. The physical and hormonal characteristics of 38 noncastrate male-to-female transsexuals and 14 noncastrate female-to-male transsexuals have been measured before and/or during therapy with various forms and dosages of hormonal therapy. All patients were hormonally and physically normal prior to therapy. Ethinyl estradiol was superior to conjugated estrogen in suppression of testosterone and gonadotropins but equal in effecting breast growth. The changes in physical and hormonal characteristics were the same for 0.1 mg/d and 0.5 mg/d of ethinyl estradiol. The female-to-male transsexuals were well managed with a dose of intramuscular testosterone cypionate of 400 mg/month, usually given 200 mg every two weeks. The maximal clitoral length reached was usually 4 cm. Higher doses of testosterone did not further increase clitoral length or suppression of gonadotropins; lower doses did not suppress the gonadotropins. Based on the information found in this study, we recommend 0.1 mg/d of ethinyl estradiol for the noncastrate male-to-female transsexual and 200 mg of intramuscular testosterone cypionate every two weeks for the noncastrate female-to-male transsexual.",
keywords = "breast, clitoris, estrogen, hormone, testosterone, transsexual",
author = "Walter Meyer and Finkelstein, {Jordan W.} and Stuart, {Charles A.} and Alice Webb and Smith, {Edward R.} and Payer, {Andrew F.} and Walker, {Paul A.}",
year = "1981",
month = "8",
doi = "10.1007/BF01565538",
language = "English (US)",
volume = "10",
pages = "347--356",
journal = "Archives of Sexual Behavior",
issn = "0004-0002",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Physical and hormonal evaluation of transsexual patients during hormonal therapy

AU - Meyer, Walter

AU - Finkelstein, Jordan W.

AU - Stuart, Charles A.

AU - Webb, Alice

AU - Smith, Edward R.

AU - Payer, Andrew F.

AU - Walker, Paul A.

PY - 1981/8

Y1 - 1981/8

N2 - The optimal hormonal therapy for transsexual patients is not known. The physical and hormonal characteristics of 38 noncastrate male-to-female transsexuals and 14 noncastrate female-to-male transsexuals have been measured before and/or during therapy with various forms and dosages of hormonal therapy. All patients were hormonally and physically normal prior to therapy. Ethinyl estradiol was superior to conjugated estrogen in suppression of testosterone and gonadotropins but equal in effecting breast growth. The changes in physical and hormonal characteristics were the same for 0.1 mg/d and 0.5 mg/d of ethinyl estradiol. The female-to-male transsexuals were well managed with a dose of intramuscular testosterone cypionate of 400 mg/month, usually given 200 mg every two weeks. The maximal clitoral length reached was usually 4 cm. Higher doses of testosterone did not further increase clitoral length or suppression of gonadotropins; lower doses did not suppress the gonadotropins. Based on the information found in this study, we recommend 0.1 mg/d of ethinyl estradiol for the noncastrate male-to-female transsexual and 200 mg of intramuscular testosterone cypionate every two weeks for the noncastrate female-to-male transsexual.

AB - The optimal hormonal therapy for transsexual patients is not known. The physical and hormonal characteristics of 38 noncastrate male-to-female transsexuals and 14 noncastrate female-to-male transsexuals have been measured before and/or during therapy with various forms and dosages of hormonal therapy. All patients were hormonally and physically normal prior to therapy. Ethinyl estradiol was superior to conjugated estrogen in suppression of testosterone and gonadotropins but equal in effecting breast growth. The changes in physical and hormonal characteristics were the same for 0.1 mg/d and 0.5 mg/d of ethinyl estradiol. The female-to-male transsexuals were well managed with a dose of intramuscular testosterone cypionate of 400 mg/month, usually given 200 mg every two weeks. The maximal clitoral length reached was usually 4 cm. Higher doses of testosterone did not further increase clitoral length or suppression of gonadotropins; lower doses did not suppress the gonadotropins. Based on the information found in this study, we recommend 0.1 mg/d of ethinyl estradiol for the noncastrate male-to-female transsexual and 200 mg of intramuscular testosterone cypionate every two weeks for the noncastrate female-to-male transsexual.

KW - breast

KW - clitoris

KW - estrogen

KW - hormone

KW - testosterone

KW - transsexual

UR - http://www.scopus.com/inward/record.url?scp=0019846543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019846543&partnerID=8YFLogxK

U2 - 10.1007/BF01565538

DO - 10.1007/BF01565538

M3 - Article

C2 - 6794543

AN - SCOPUS:0019846543

VL - 10

SP - 347

EP - 356

JO - Archives of Sexual Behavior

JF - Archives of Sexual Behavior

SN - 0004-0002

IS - 4

ER -